ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Evolving Standards of Care

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

on: April 21, 2025In: Evolving Standards of Care
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

In this Q&A, Dr. Luis E. Raez and nurse practitioner Beth Sandy discuss recently reported MARIPOSA data in the context of current standard of care and provide best practices for therapeutic selection and patient education. Read more

LUMINOSITY Subgroup Analysis Shows Similar Results for Asian Patients Compared to Global Population

Fred Gebhart
on: November 12, 2024In: Evolving Standards of Care, Meeting News, WCLC News
LUMINOSITY Subgroup Analysis Shows Similar Results for Asian Patients Compared to Global Population

Dr. Hidehito Horinouchi said treatment with Teliso-V demonstrated promising and durable responses in Asian cohort, particularly those with high c-Met expression. Read more

TROPION-Lung01 Demonstrates Improvement in PFS; OS Improvement Fails to Reach Statistical Significance

Fred Gebhart
on: November 12, 2024In: Evolving Standards of Care, Meeting News, WCLC News
TROPION-Lung01 Demonstrates Improvement in PFS; OS Improvement Fails to Reach Statistical Significance

Dr. Jacob Sands presented findings that show a progression-free survival advantage for Dato-DXd versus docetaxel in the non-squamous cohort. Read more

First Presidential Symposium to Explore Practice-Changing Research in Lung Cancer Screening, Immune Oncology

Fred Gebhart
on: September 07, 2024In: Evolving Standards of Care, Meeting News, Screening/ED, WCLC News
First Presidential Symposium to Explore Practice-Changing Research in Lung Cancer Screening, Immune Oncology

The session will also include late-breaking data from HARMONi-2, NeoCOAST-2, and TROPION-Lung01 as well as an address from IASLC President Dr. Paul Van Schil. Read more

Gender Disparity in Lung Cancer

Jyoti Patel, MD
+more
on: July 23, 2024In: Evolving Standards of Care
Gender Disparity in Lung Cancer

Drs. Jyoti Patel and Khyati Somayaji Dasika say the increased burden of lung cancer on women underscores the necessity for gender-sensitive approaches in healthcare policy, research, and clinical practice. Read more

BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population

John Austin
on: July 23, 2024In: Evolving Standards of Care, Meeting News
BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population

While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population. Read more

Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2

Erin Jungmeyer
on: July 23, 2024In: Evolving Standards of Care, Meeting News
Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2

In an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative. Read more

Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases

John Austin
on: July 09, 2024In: Evolving Standards of Care, Meeting News
Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases

Dr. Anne-Marie C. Dingemans said the data indicate that it is safe to prescribe tarlatamab for these patients now that it has been approved by the US FDA. Read more

Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC

Fred Gebhart
on: July 09, 2024In: Evolving Standards of Care, Meeting News
Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC

Presenter Dr. Bob T. Li said further study is needed, particularly given the positive PFS results in PDL-1-negative patients, who represent an unmet medical need. Read more

Osimertinib Plus Chemotherapy May Improve CNS Activity in Advanced EGFR-positive NSCLC

Marthe S. Paats, MD, PhD
+more
on: July 09, 2024In: Evolving Standards of Care
Osimertinib Plus Chemotherapy May Improve CNS Activity in Advanced EGFR-positive NSCLC

However, Drs. Marthe S. Paats and Anne-Marie C. Dingemans caution that in the light of the toxicity profile, the combination may not be the best option for all patients. Read more

CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date

Erin Jungmeyer
on: June 25, 2024In: Evolving Standards of Care, Meeting News
CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date

When presenting the data, Dr. Benjamin Solomon said first-line lorlatinib offers unprecedented improvement in outcomes for patients with advanced ALK+ non-small cell lung cancer. Read more

‹123456›»

SEARCH ILCN

Archives

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy